ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items turns negative

Q1 FY2026 other non-cash items was -$745K, compared with $0 a year earlier. Trailing-twelve-month other non-cash items was -$1.81M.

Context

  • Other non-cash items amounted to 3.6% of revenue in FY2025, up 3.6 pp from a year earlier.
  • Other non-cash items increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other non-cash items holds near -$745K or moves back toward the trailing-twelve-month quarterly average of -$452.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$745K-167.2% QoQ
Last fiscal yearDec 2025
-$3.03M— YoY
LTMMar 2026
-$1.81M-4.9% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
(3.03M) USD
Year-over-year change
—

Other Non-Cash Items vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's LTM Mar 2026 other non-cash items of $1.81M is the smallest of the 4 companies compared; the peer median is $11.41M.
  • Its year-over-year change of -4.9% is the lowest of 4, against a peer median of +160.6%.
  • Other non-cash items amounts to 1.8% of revenue for SPRY, versus a peer median of 22.7%.
SPRY Competitors Peer median
Other Non-Cash Items for SPRY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNKDMannKind CorporationLTM Mar 2026$106.69M +550.7%+40.1%29.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$11.41M +7.5%+23.4%22.7%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$3.71M +160.6%+3.6%1.2%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$1.81M -4.9%—1.8%
Peer median (excluding SPRY) $11.41M+160.6%+23.4%22.7%

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Depreciation & Amortization213K319K73K(7.18M)1.37M
Deferred Income Tax00000
Stock-Based Compensation2.83M5.84M9.24M14.53M22.1M
Change in Working Capital(356K)(12.75M)(7.33M)(1.81M)(20M)
Accounts Receivables000(8.18M)(17.21M)
Inventory000(5.95M)(21.99M)
Accounts Payables0(10.29M)(2.78M)16.43M18.88M
Other Working Capital(356K)(2.47M)(4.55M)(4.12M)306K
Other Non-Cash Items(4K)1.2M(6.88M)0(3.03M)
Operating Cash Flow(17.56M)(40.08M)(59.27M)13.55M(170.87M)
Capital Expenditures(55K)(199K)(175K)(563K)(339K)
Acquisitions (Net)00000
Purchases of Investments00(272.01M)(356.04M)(242.03M)
Sales of Investments00185M258M307M
Other Investing Activities000(7.5M)(7.86M)
Investing Cash Flow(55K)(199K)(87.18M)(106.1M)56.77M
Debt Repayment(1.82M)(8.68M)069.38M96.26M
Common Stock Issued169K570K6.9M3.02M5.68M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0198.84M002.66M
Financing Cash Flow53.16M190.73M6.9M72.4M104.6M
Effect of Forex Changes00000
Net Change in Cash35.54M150.46M(139.55M)(20.15M)(9.5M)
Free Cash Flow(17.62M)(40.28M)(59.44M)12.99M(171.21M)

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.